Global Cell Therapy Market By Therapy Type [Allogeneic Therapies (Stem Cell Therapies (Hematopoietic Stem Cell Therapies, Mesenchymal Stem Cell Therapies), Non-Stem Cell Therapies (Keratinocytes & Fibroblast-based Therapies, Others), Autologous Therapies (Stem Cell Therapies (BM, Blood, & Umbilical Cord-derived Stem Cells, Adipose derived cells, Others), Non-Stem Cell Therapies (T-Cell Therapies, CAR T Cell Therapy, T Cell Receptor (TCR)-based, Others)] Therapeutic Area (Oncology, Cardiovascular Disease (CVD), Musculoskeletal Disorders, Dermatology, Others), By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Cell Therapy Market Overview

The global cell therapy market size is expected to be worth around USD 26.8 Billion by 2033, from USD 5.6 Billion in 2023, growing at a CAGR of 16.9% during the forecast period from 2023 to 2033.

Cell therapy is a technology that replaces damaged or dysfunctional cells with healthy functioning cells. Because stem cells can differentiate into the cells needed to repair damaged or defective tissue, they are the main cells used in advanced therapies.

In addition, cell therapy can be used to develop regenerative medicines. Regenerative medicine is a multidisciplinary area that focuses on maintaining, improving, or restoring cell function, tissue, and cell functions using methods mainly related to cell therapy.

Key Takeaways

• The cell therapy market size will grow from USD 5.6 Billion in 2023 to about USD 26.8 Billion by 2033.
• This growth represents a CAGR of 16.9% from 2023 to 2033.
• In 2023, Autologous Therapies, which use a patient’s own cells, dominate the market with more than a 91% share.
• Oncology treatments using cell therapy have a 37% market share in 2023, showing how big a role they play in cancer treatments.
• Treatments targeting Cardiovascular Disease (CVD), like heart issues, are making a big impact on heart-related health problems.
• In 2023, North America will account for 53.4% of the global cell therapy market.
• Five of the world’s top eight universities specializing in stem cell therapy are located in the U.S.
• In the Asia Pacific region, the cell therapy industry is expected to grow at a rate of 14.6% in the coming years.

Therapy Type Analysis

In 2023, Autologous Therapies held a dominant market position, capturing more than a 91% share. These therapies use a patient’s own cells, making them more personalized. Within this segment, stem cell therapies like BM, Blood, & Umbilical Cord-derived Stem Cells and Adipose derived cells are popular. Additionally, there are non-stem cell therapies such as T-Cell Therapies, with CAR T Cell Therapy and T Cell Receptor (TCR)-based therapies showing potential.

Allogeneic Therapies involve using cells from donors. This category showcases varied therapies like Hematopoietic Stem Cell Therapies and Mesenchymal Stem Cell Therapies. Moreover, non-stem cell options like Keratinocytes & Fibroblast-based Therapies are also gaining traction.

Therapeutic Area Analysis

In 2023, Oncology led the cell therapy market, securing a significant 37% market share. This dominance underscores the important role in cell therapies, revolutionizing cancer treatment strategies. Cell therapies for Cardiovascular Disease (CVD) target heart and circulatory system conditions, representing a significant breakthrough in tackling heart-related ailments.

Musculoskeletal Disorders also found prominence in the market. Cell therapies in this segment focus on treating conditions affecting muscles, bones, and the supporting structures. Dermatology-based cell therapies are on the rise too, catering to a range of skin-related conditions and offering innovative treatment options.

Key Market Segments

Therapy Type

• Allogeneic Therapies
  • Stem Cell Therapies
    • Hematopoietic Stem Cell Therapies
    • Mesenchymal Stem Cell Therapies
  • Non-Stem Cell Therapies
    • Keratinocytes & Fibroblast-based Therapies
    • Others
• Autologous Therapies
  • Stem Cell Therapies
    • BM, Blood, & Umbilical Cord-derived Stem Cells
    • Adipose derived cells
    • Others
  • Non-Stem Cell Therapies
    • T-Cell Therapies
    • CAR T Cell Therapy
    • T Cell Receptor (TCR)-based
    • Others

Therapeutic Area

• Oncology
• Cardiovascular Disease (CVD)
• Musculoskeletal Disorders
• Dermatology
• Others

Driver

More people are getting chronic and infectious diseases.

Cell therapy is like a detective tool for big health problems like HIV/AIDS, cancer, and other infections. Thanks to cell therapy, doctors and scientists can better understand these diseases and how to treat them. Plus, with more people in the world and the changing climate, we see new diseases popping up. Cell therapy can help tackle these new health challenges.

Restraint

Cell research is expensive and doesn’t always work out.

Researching cell therapies, like stem cell treatments, needs top-notch tools and follows strict rules. All this makes the research pricey. This is tough for smaller groups or companies who don’t have a lot of money. They might not be able to afford the high-end tools they need.

Opportunity

Making treatments just for you.

Imagine medicines made just for you! That’s what personalized medicine is about. It looks at your unique body, surroundings, and habits to decide the best treatment. This special approach is growing, especially in cancer care. It’s like a tailor-made suit, but for health!

Challenge

Hard for small companies to survive.

Big companies like Thermo Fisher and Merck have a big piece of the cell therapy market pie. This makes it tough for the little guys or newcomers to get a slice. Big companies have more money for research, while small ones struggle to keep up. It’s like a big fish in a small pond, making it hard for the small fish to grow.

Regional Analysis

North America will hold 53.4% of the world’s market share in 2023. This large Cell Therapy market share can be attributed largely to numerous centers and institutes involved in stem cell therapy R&D. Five of the 8 leading universities worldwide are U.S.-based. These include Institute for Stem Cell Biology and Regenerative Medicine, Yale Stem Cell Center, and Harvard Stem Cell Institute.

Asia Pacific’s field cell therapy industry is expected to grow 14.6% during the forecast period. It is expected that the region’s emerging economies will generate more revenue sources due to the increased investment made by both developers and consumers in advanced medical treatments. Many stem cell alliances in Asia aim to coordinate and focus on R&D. A flexible legal framework has led to patients from Western countries migrating to Asian countries to seek treatment.

Key Regions and Countries

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Russia
  • Spain
  • Rest of Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Rest of Asia-Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • GCC
  • South Africa
  • Israel
  • Rest of MEA

Key Players Analysis

U.S. FDA approvals have been granted to numerous companies for stem-cell therapy for different diseases and infections. Stemedica Cell Technologies, Inc. was granted Investigational New Drug Approval by FDA to conduct phase II trials on intravenously administered allogeneic MSCs for covid-20 patients. They are attractive as a novel treatment for COVID-19 due to their immunomodulatory and immunogenicity.

Advanced cell therapy manufacturing includes some major key market players: Novartis AG, Gilead Sciences, Inc., Bristol-Myers Squibb Company, Johnson & Johnson Services, Inc, JCR Pharmaceuticals Co., Ltd., Tego Science, Atara Biotherapeutics, Takeda Pharmaceutical Company Limited, Bluebird Bio, Inc. and Dendreon Corp.

Маrkеt Кеу Рlауеrѕ

• Novartis AG
• Gilead Sciences, Inc.
• Bristol-Myers Squibb Company
• Johnson & Johnson Services, Inc
• JCR Pharmaceuticals Co., Ltd.
• Tego Science
• Atara Biotherapeutics
• Takeda Pharmaceutical Company Limited
• Bluebird Bio, Inc.
• Dendreon Corp.

Recent Development

• October 2023 – Allogene Therapeutics Announces Positive Topline Data from Phase 1 TRANSCEND Study of AlloCAR T38 in Patients with Relapsed or Refractory Multiple Myeloma (rrMM). The data showed that AlloCAR T38 produced high overall response rates (ORRs) and deep and durable responses in rrMM patients, with a manageable safety profile.
• September 2023 – Kite Pharma Announces Positive Topline Data from Phase 3 ZUMA-7 Study of Yescarta (axicabtagene ciloleucel) in Patients with Relapsed or Refractory Follicular Lymphoma (r/r FL). The data showed that Yescarta significantly improved progression-free survival (PFS) and overall survival (OS) in patients with r/r FL.
• August 2023 – Novartis Announces Positive Topline Data from Phase 3 CARVENO Study of Kymriah (tisagenlecleucel) in Patients with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL). The data showed that Kymriah significantly improved PFS and OS in patients with r/r LBCL.
• July 2023 – Bristol Myers Squibb Announces Positive Topline Data from Phase 3 KarMMa Study of Breyanzi (lisocabtagene maraleucel) in Patients with Relapsed or Refractory Multiple Myeloma (rrMM). The data showed that Breyanzi significantly improved PFS and OS in patients with rrMM.
• June 2023 – Gilead Sciences Announces Positive Topline Data from Phase 3 ZUMA-3 Study of Yescarta (axicabtagene ciloleucel) in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). The data showed that Yescarta significantly improved PFS and OS in patients with r/r DLBCL.

Report Scope